Study of INNA-051 to prevent viral respiratory illness in healthy adults
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether INNA-051 can help prevent respiratory infections caused by viruses in healthy adults aged 18 to 45. It may be an option if you are at higher risk of catching such infections due to your living or work situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old and in good overall health.
- You are at increased risk for viral respiratory infections (e.g., live in crowded housing, work in healthcare, childcare, or other high-exposure jobs).
- You do not have diabetes, asthma, or any chronic lung condition.
- You have not had a vaccine for RSV or COVID-19 in the last 6 months.
- You are not currently pregnant, breastfeeding, or planning to become pregnant; if you can become pregnant, you must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how safe and tolerable different doses of Ingavirin Forte are in healthy people. It helps find the right dose for future studies.
This trial tests how the body reacts to a specific flu virus (pH1N1) in a controlled setting. Healthy volunteers are exposed to the virus to help researchers understand the infection and test treatments. You will be monitored closely and given antiviral medication if needed.
This study tests an inhaled study drug (SNG001) for adults on a breathing machine in the ICU due to a viral lung infection. The goal is to see if the drug can help patients recover faster.
This study compares two versions of an antiviral medicine called Ingavirin to see how your body processes them and whether they are safe. Researchers will give you the medicine on an empty stomach and after eating to understand how food affects how your body absorbs it.
This study tests an experimental RSV vaccine (IN006) in healthy adults to check its safety and how well it triggers an immune response. It may help protect against respiratory syncytial virus (RSV), which can cause serious lung infections.
This trial looks at respiratory viruses caught in the hospital. If you are an adult patient or healthcare worker with flu-like symptoms that started while in the hospital, you may help researchers learn more about these infections.
Hear when a new Viral Respiratory Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.